louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00911768: Effect of Korean Red Ginseng (KRG) on Dry Mouth
Official title: PMS Clinical Study of Korean Red Ginseng Powder on Dry Mouth and Salivary Flow Rates in Xerostomatic Populations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Xerostomia
Keywords: Xerostomia
Panax ginseng(Korean Red Ginseng)
Visual Analogue Scale
Salivary Flow Rates
Lead sponsor: The Korean Society of Ginseng
Sponsor class: OTHER
First posted: 2009-06-02
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 76
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of KRG (Korean Red Ginseng) on Dry Mouth (Xerostomia).

Detailed description: Korean Red Ginseng

* Worldwide use
* A main herb of old oriental prescriptions for dry mouth
* Need for correct information by RCT

Eligibility criteria: Inclusion Criteria:

* Dry mouth patients

Exclusion Criteria:

* Sjögren syndrome
* Irradiation related xerostomia
* Severe psychiatric diseases
* pregnancy or breast feeding women

Primary outcomes:
measure: Visual Analogue Scale of Subjective Dry Mouth
timeFrame: 8 weeks
Secondary outcomes:
measure: Stimulated Salivary Flow Rates
timeFrame: 8 weeks
measure: Unstimulated Salivary Flow Rates
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kyung Hee East-West Neo Medical Center
Study officials:
affiliation: Kyung Hee East-West Neo Medical Center
name: Jae-Woo Park, K.M.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06392568: Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units
Official title: Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units: A Prospective Multicenter National Observational Study (NOSOREA-3)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cross Infection
Carbapenem Resistant Bacterial Infection
Vancomycin-Resistant Enterococcal Infection
Critical Illness
Keywords: Critical care
Healthcare Associated Infections
Drug resistance
Lead sponsor: Abderrahmane Mami Hospital
Sponsor class: OTHER
First posted: 2024-04-30
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult ICU patients admitted during the study period

Brief summary: Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.

Detailed description: In 2022, a previous one-day point-prevalence multicenter study (NOSOREA2, NCT05547646) showed that most prevalent pathogens causing healthcare-associated infections were carbapenem resistant enterobacteriaceae. In 2017, (NOSOREA1, LA TUNISIE MEDICALE - 2018 ; Vol 96 (10/11)), most prevalent pathogens were non-fermenting pathogens.

Faced with this major epidemiological change within Tunisian ICUs, we decided to launch a 3rd survey under the aegis of the 'Association tunisienne de réanimation'. We aimed to investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus. So we conducted a multicenter prospective collection that will take place over 2 months.

Eligibility criteria: Inclusion Criteria:

* Adult ICU patients admitted during the study period

Exclusion Criteria:

* none

Primary outcomes:
measure: Highly resistant bacterial healthcare associated infections
timeFrame: 2 months
measure: Epidemiological features of Highly resistant bacterial healthcare associated infections healthcare associated infections in ICU
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ariana
country: Tunisia
facility: Abderrahmen Mami
state: Tunis
Study officials:
affiliation: Abderrahmen Mami Hospital
name: Amira JAMOUSSI, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02991768: Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients
Official title: Budesonide for Mycophenolic Acid (MPA)-Induced Diarrhea in Renal Transplant Recipients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Diarrhea
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2016-12-13
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication.


Eligibility criteria: Inclusion Criteria:

* Kidney transplant recipients \> 1 months post-transplant,
* No history of chronic diarrhea pre-transplant,
* \>3 watery/soft stools after transplant on at least 4 days in the week without anti-diarrheal for at least 2 weeks or using anti-diarrheals for at least 4 days in the week \> 2 weeks
* Subjects on at least 180mg twice a day of mycophenolate-sodium or 250 mg twice a day of cellcept

Exclusion Criteria:

* Diagnosis of any known colonic diseases (i.e. Crohn's disease, ulcerative colitis, ischemic colitis, Celiac disease), partial colonic resection, small bowel resection, history of cholecystectomy, Irritable Bowel Syndrome, fecal Incontinence, Bacterial overgrowth, infectious diarrhea (c difficle, cryptospora, giardia, isospora, Human Immunodeficiency Virus), Cytomegalovirus colitis
* Subjects with recent acute rejection treated with high dose steroids
* Subjects taking Boswellia serrata extract, over-the-counter herbs, cholestyramine, nonsteroidal salicylates (other than daily ASA)
* Subjects with active malignancy, liver cirrhosis, active peptic ulcer disease, known intolerance or resistance to budesonide, pregnancy, breast-feeding, mental retardation
* Unable to provide informed consent

Primary outcomes:
measure: Complete Remission of Diarrhea
timeFrame: Week 8
Secondary outcomes:
measure: Change in Gastrointestinal Symptom Rating Scale (GSRS)
timeFrame: Change from Baseline to Week 8
measure: Change in Gastrointestinal Symptom Rating Scale (GSRS)
timeFrame: Change from Baseline to Week 16
measure: Change in Gastrointestinal Quality of Life Index (GIQLI)
timeFrame: Change from Baseline to Week 8
measure: Change in Gastrointestinal Quality of Life Index (GIQLI)
timeFrame: Change from Baseline to Week 16
measure: MPA Dose
timeFrame: Change from Baseline to Week 8
measure: MPA Dose
timeFrame: Change from Baseline to Week 16
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: University of Kansas Medical Center
name: Pooja Budhiraja, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04520568: High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery
Official title: Preventing Deoxygenation With High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chronic Obstructive Pulmonary Disease
Respiratory Failure
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2020-08-20
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: High-flow nasal cannula (HFNC) is a device that delivers10 to 70 L min-1 of heated, humidified 100% oxygen via nasal route. It provides positive airway pressure, decreases dyspnea, decreases the work of breathing, and improves comfort

Detailed description: Beneficial effects of the HFNC system have been assessed based on 3 physiologic conditions: decreased dead space, a high concentration of inspiratory oxygen, and positive pressure in the oro-laryngeal cavity.Studies have shown that it improves oxygenation in various perioperative settings such as the apneic patients, patients with respiratory failure , and patients undergoing bronchoscopy

Eligibility criteria: Inclusion Criteria:

* ASA physical status II and III,
* undergoing VATS

Exclusion Criteria:

* refusal of patients
* extrem of age

Primary outcomes:
measure: arterial partial pressures of oxygen
timeFrame: two hours
measure: pH measurement
timeFrame: two hours
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Rehab Abd Elraof Abd Elaziz
Study officials:
affiliation: Alexandria University
name: Rehab A. Abd Elaziz, Ass.Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00831168: BEADI - The Bliss Cluster Randomised Control Trial on the Effects of Active Dissemination of Information (BEADI)
Official title: The Bliss Cluster Randomised Control Trial on the Effects of Active Dissemination of Information on Outcomes of Premature Babies.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Premature Babies
Keywords: neonatal
premature babies
healthcare research
Babies born before 27 weeks gestation
Lead sponsor: Confidential Enquiry into Maternal and Child Health
Sponsor class: OTHER
First posted: 2009-01-28
Enrollment: 200
Sex: ALL
Minimum age (years): 22
Maximum age (years): 27
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: BEADI is a dissemination trial, on standards of care of premature babies. The main objective of BEADI is to assess whether an innovative 'active' strategy for the dissemination of neonatal information (evidence reviews, interactive training workshop, benchmarking and feedback, and ongoing support) is more likely to lead to changes in policy and practice than the traditional (more passive) forms of dissemination in English neonatal units.

BEADI will focus on three areas of neonatal care for premature (22+0 to 26+6 weeks' gestation) babies born in England: timing of surfactant therapy, staffing for resuscitation at delivery, and temperature control (in line with the main Project 27/28 findings ). However, the approach is applicable to a wide variety of clinical policies and practice.

The BEADI study has been granted ethical approval by MREC to use a subset of data collected by EPICure2 up until 31st December 2006 (pre-intervention data). For the post-intervention data, ethical approval has been granted for CEMACH to continue data collection against the three clinical areas using a subset of data items captured in the PN:E2 form, for the three month period between 1st January - 31st March 2007. Local research and development departments of each trust have also been contacted.


Eligibility criteria: Inclusion Criteria:

* Hospital staff : Lead neonatologist for clinical governance in each maternity hospital in England.
* Babies born in England before 27 weeks gestation between January 2006 - 31st March 2007

Primary outcomes:
measure: Assess whether an innovative 'active' strategy for the dissemination of neonatal research findings, recs and national guidelines is more likely to lead to changes in policy and practice than the traditional,passive forms of dissemination in the UK.
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Confidential Enquiry into Maternal and Child Health
name: Dominique Acolet
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04016168: Idiopathic Pulmonary Fibrosis and Serum Bank
Official title: Idiopathic Pulmonary Fibrosis and Serum Bank
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Idiopathic Pulmonary Fibrosis
Lung Diseases, Interstitial
Keywords: Biomarkers
CD163
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2019-07-11
Enrollment: 903
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.

Brief summary: Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults. It is a fibroproliferative, irreversible disease of unknown cause, usually progressive, occurring mainly from the age of 60 and limited to the lungs. IPF is a serious disease with a median survival rate at diagnosis of 3 years.

The aim of the study is to set up a biocollection of serum from patients in a context of idiopathic DILD and a possible or confirmed diagnosis of common interstitial lung disease by chest CT.

Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.

Detailed description: This study will initially focus on circulating serum CD163 markers, but a broader proteomics approach could be considered in a second phase to look for other markers of lung diseases.

Eligibility criteria: Inclusion Criteria:

* Patients seen on an outpatient basis and in stable or acute condition
* Patient over 18 years of age.
* The inclusion criteria will be those edited by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) to diagnosis IPF

Exclusion Criteria:

* Patients who are unable or unwilling to sign the consent.

Primary outcomes:
measure: Determination of circulating CD163 serum concentration
timeFrame: Through study completion, an average of 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Rennes University Hospital - Service de Pneumologie
Study officials:
affiliation: University Hospital of Rennes
name: Stéphane JOUNEAU, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02532868: A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
Official title: A Phase I Dose Escalation Study of MK0457 Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Cancer
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2015-08-26
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and tolerability of MK-0457(VX-680), an Aurora kinase inhibitor, in participants with advanced solid tumors. Bioavailability of the oral formulation will also be assessed. The primary study hypothesis is that administration of MK-0457 is sufficiently safe and tolerated to permit further study.


Eligibility criteria: Inclusion Criteria:

* Patients who are at least 18 years of age with recurrent or non-responsive solid tumors, or cancers for which standard therapy does not exist.

Exclusion Criteria:

* Patients who have had treatment with any investigational therapy within the past 30 days.
* Patients who have certain types of blood cancers such as leukemia or lymphoma.
* Patients who have uncontrolled congestive heart failure (CHF), chest pains, or had a heart attack within the past 3 months, or have undergone bone marrow or stem cell transplantation.
* Patient is pregnant or nursing.

Primary outcomes:
measure: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
timeFrame: Up to 21 days
Secondary outcomes:
measure: Change in standard uptake value (SUV) in fluorodeoxyglucose positron emission tomography (FDG-PET) scans
timeFrame: Predose, and at end of Cycles 2 and 6 (up to approximately 4 months)
measure: Overall Tumor Response Per Response Evaluation Criteria in Solid Tumors (RECIST)
timeFrame: Pre-dose through post-study visit (up to 3 years)
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Feb;67(2):305-14. doi: 10.1007/s00280-010-1318-9. Epub 2010 Apr 13.
Clinical trial NCT05647668: Laparoscopic Total vs Partial Fundoplication in Patients With Atypical Symptoms of Gastroesophageal Reflux Disease
Official title: A Prospective Randomized Trial on Laparoscopic Total vs Partial Fundoplication in Patients With Atypical Symptoms of Gastroesophageal Reflux Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastroesophageal Reflux Disease
Lead sponsor: Danylo Halytsky Lviv National Medical University
Sponsor class: OTHER
First posted: 2022-12-12
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: One hundred and twenty patients with documented extraesophageal symptoms of gastroesophageal reflux disease were randomized to either undergo floppy Nissen (n= 60) or Toupet fundoplication (n= 60). Symptom scores of extraesophageal symotoms and quality of life were prospectively evaluated. Analysis of the treatment results showed a significant improvement of symptoms in both patient groups.Quality of life improved substantially at short- and long-term follow up in both groups and there were no statistical differences between the groups in this parameter.


Eligibility criteria: Inclusion Criteria:

* extraesophageal symptoms of gastroesophageal reflux disease
* undergoing surgery for gastroesophageal reflux disease
* at least 18 years old

Exclusion Criteria:

* patients under the age of 18 years
* previous anti-reflux surgery, other surgical procedures in the vicinity of the gastroesophageal junction
* major psychiatric illness
* unstable chronic illnesses (such as diabetes)
* inability of the patient to complete the survey.

Primary outcomes:
measure: Symptom scores of throat clearing, globus sensation, cough, throat pain, vocal changes.
timeFrame: 24 month
Secondary outcomes:
measure: Reflux symptom index (RSI) score
timeFrame: 24 months
measure: laryngopharyngeal reflux-health-related quality of life (LPR-HRQL) questionnaire score
timeFrame: 24 months
Other outcomes:
Locations:
city: Lviv
country: Ukraine
facility: Danylo Halytsky Lviv National Medical University
Study officials:
References:
Clinical trial NCT00698672: RSA-Study of Cemented Hip Prostheses With Five Different Articulations
Official title: A Prospective Randomized RSA-Study of Cemented Hip Prostheses With Five Different Articulations
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Arthritis
Keywords: RSA
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
First posted: 2008-06-17
Enrollment: 150
Sex: ALL
Minimum age (years): 59
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare wear and migration of the following hip prostheses:

1. Charnley monoblock 22.2mm caput and OGEE polyethylene acetabular component
2. Spectron EF stem with Reflection polyethylene cup and 28 mm CoCr caput
3. Spectron EF stem with XLPE cup and 28 mm CoCr caput
4. Spectron EF stem with Reflection polyethylene cup and 28 mm Oxinium caput
5. Spectron EF stem with XLPE cup and 28 mm Oxinium caput

Detailed description: Detailed description in:

Wear and migration of highly cross-linked and conventional cemented polyethylene cups with cobalt chrome or Oxinium femoral heads: a randomized radiostereometric study of 150 patients.

Kadar T, Hallan G, Aamodt A, Indrekvam K, Badawy M, Skredderstuen A, Havelin LI, Stokke T, Haugan K, Espehaug B, Furnes O.

J Orthop Res. 2011 Aug;29(8):1222-9. doi: 10.1002/jor.21389

Eligibility criteria: Inclusion Criteria:

* arthritis
* dysplasia

Exclusion Criteria:

* obesitas
* charcots
* paget
* malignancy

Primary outcomes:
measure: wear
timeFrame: 2 years
Secondary outcomes:
measure: migration
timeFrame: 2 years
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Haukeland University Hospital
Study officials:
affiliation: Haukeland University Hospital
name: Thomas Kadar, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06091072: Image-guided Navigation During Robotic Sentinel Node Removal
Official title: Feasibility of in Vivo Image-guided Navigation During Robotic Sentinel Node Removal
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: The Netherlands Cancer Institute
Sponsor class: OTHER
First posted: 2023-10-19
Enrollment: 55
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: One group to evaluate the feasibility of the proposed method.
Primary purpose: OTHER

Brief summary: Image-guided navigation based on pre-operative imaging can give the surgeon more insight into the location of the sentinel nodes in relation to other anatomical structures. The purpose of the study is to investigate the feasibility of image-guided navigation during robot-assisted surgery to treat cancer in the pelvic area.Ultimately, the application of navigation during robot-assisted sentinel node dissection could potentially improve the outcome of surgery for the patient.

Detailed description: Image-guided navigation surgery allows for full utilization of pre-operative imaging during surgery, and has the potential of reducing both irradical resections and morbidity. It has successfully been applied in the AvL for open abdominal surgery, however more and more surgeries are being performed less invasive using robot surgery. Rapid extension of robot-assisted surgery has increased the need for robot-compliant image-guided techniques.

Unfortunately, tactile feedback is lacking in these robotic surgeries, which increases the additional value of image-guided navigation. In this study, patients will undergo an abdominal sentinel node dissection in order to evaluate the actual technical benefit of robotic navigation. This is the first feasibility study towards clinical implementation of the navigation setup into robot-assisted image-guided navigation surgery. The results of this study will be the base for new studies, evaluating the clinical benefit of image-guided navigation for robot surgeries.

Eligibility criteria: Inclusion Criteria:

* Scheduled for abdominal robotic sentinel node resection
* ≥ 18 years old
* Provided written 'informed consent'
* Sentinel nodes should be fixed relative to retroperitoneal structures or major vessels.

Exclusion Criteria:

* Metal hip implants / implants in the pelvic area
* Pacemaker, defibrillator

Primary outcomes:
measure: Feasibility of image-guide assisted sentinel node removal
timeFrame: One day
Secondary outcomes:
measure: Usability of image-guided navigation
timeFrame: One day
measure: Time
timeFrame: One day
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Netherlands Cancer Institute
state: North Holland
Study officials:
References: